Differences

This shows you the differences between two versions of the page.

--- home:othertreatments:chemotherapy [11.13.2011] – [Rituximab] paulalbert
+++ home:othertreatments:chemotherapy [11.13.2011] – [Rituximab] paulalbert
@@ Line 43: / Line 43: @@
-In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with CFS. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pubmed>long:22039471}})) This positive result may be due to the fact that Rituximab is a strong immunosuppressant. It may be telling to see a follow up of the patients who received the drug ten or even fifteen years from now.
+In 2011, a Norwegian study published in //PLoS One// studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.(({{pubmed>long:22039471}})) This positive result may be due to the fact that Rituximab is a strong immunosuppressant. It may be telling to see a follow up of the patients who received the drug ten or even fifteen years from now.
 =====  Patient interviews  =====

home/othertreatments/chemotherapy.txt · Last modified: 09.14.2022 by 127.0.0.1